Renal Denervation Devices Market

Renal Denervation Devices Market by Technology (Radiofrequency-Based Renal Denervation, Ultrasound-Based Renal Denervation, Micro-infusion-Based Renal Denervation, and Cryoablation Renal Denervation), Product Type (Catheters, Guidewires, and Accessories), Application (Hypertension, Heart Failure, Chronic Kidney Disease (CKD), and Others), End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of hypertension, rising incidence of cardiovascular diseases closely associated with hypertension, expansion of renal denervation devices in other clinical applications, and increase in product development activities across the globe.

The global renal denervation devices market is estimated to grow at a CAGR of 14.34% during the forecast period from 2025 to 2032. The rising prevalence of hypertension and the growing incidence of cardiovascular diseases closely linked to uncontrolled blood pressure is significantly driving the demand for renal denervation devices. Additionally, the expansion of these devices into other clinical applications, such as heart failure and chronic kidney disease, has broadened their market potential. Continuous advancements in technology and increased product development activities by key players globally are further enhancing the safety, efficacy, and adoption of these devices, collectively fueling the growth of the renal denervation devices market during the forecast period from 2025 to 2032.

Renal Denervation Devices Market Dynamics:

According to the World Health Organization (2023), an estimated 1.28 billion adults aged 30–79 years worldwide have hypertension, most (two-thirds) living in low- and middle-income countries. Additionally, an estimated 46% of adults with hypertension were unaware that they had the condition of hypertension. Hypertension is a leading risk factor for severe cardiovascular conditions, such as heart attacks, strokes, and kidney failure, creating an urgent need for effective and long-lasting treatment solutions. These minimally invasive renal denervation devices target overactive renal nerves to reduce blood pressure, providing a ground-breaking alternative for patients unresponsive to conventional therapies and thereby boosting the overall market of renal denervation devices across the globe.

Additionally, according to the World Heart Federation (2024), approximately 60 million population were affected by atrial fibrillation which was one of the most common types of irregular heartbeat, or arrhythmia. It can increase the risk of blood clots, heart failure, and stroke. Additionally, as per the same source people with atrial fibrillation are 5X times more likely to suffer a stroke. Hypertension is a primary risk factor for atrial fibrillation, a condition characterized by irregular heart rhythms that can lead to complications like blood clots, strokes, and heart failure. Similarly, uncontrolled hypertension increases the likelihood of ischemic and hemorrhagic strokes, further highlighting the need for effective blood pressure management. Renal denervation offers a promising solution by targeting the overactive sympathetic nervous system, which plays a critical role in elevated blood pressure and the progression of atrial fibrillation and stroke-related complications. As studies demonstrate the potential of renal denervation to stabilize blood pressure levels and reduce cardiovascular risks, its application in managing patients with atrial fibrillation and preventing recurrent strokes is gaining momentum.

Furthermore, the increase in strategic activities among the key market players is further boosting the market of restorable vascular scaffolds across the globe. For instance, in November 2023, the U.S. Food and Drug Administration (FDA) approved the Medtronic Symplicity Spyral™ renal denervation system for use in the United States. The system uses radio frequency to disrupt overactive nerves in the kidneys and help lower blood pressure.

Thus, the factors mentioned above are expected to boost the overall market of renal denervation devices across the globe during the forecast period from 2025 to 2032.

However, the competition with existing therapies and the risk of complications associated with renal denervation devices may hinder the future market of renal denervation devices across the globe during the forecasted period.

Renal Denervation Devices Market Segment Analysis:

Renal Denervation Devices Market by Technology (Radiofrequency-Based Renal Denervation, Ultrasound-Based Renal Denervation, Micro-infusion-Based Renal Denervation, and Cryoablation Renal Denervation), Product Type (Catheters, Guidewires, and Accessories), Application (Hypertension, Heart Failure, Chronic Kidney Disease (CKD), and Others), End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, and Others)

In the technology segment of the renal denervation devices market, the ultrasound-based renal denervation segment is expected to hold a significant share in 2024. Ultrasound systems deliver high-frequency sound waves to target nerve endings surrounding the renal arteries. This non-contact mechanism ensures more uniform and precise nerve ablation, reducing the likelihood of incomplete treatment and enhancing efficacy. Additionally, ultrasound-based devices are minimally invasive, reducing the procedure time and associated complications, which increases their appeal among both physicians and patients.

One of the primary drivers for the adoption of ultrasound-based renal denervation is its potential to treat resistant hypertension a condition unresponsive to conventional pharmacological therapies. As the prevalence of hypertension rises globally, particularly in aging populations, the demand for effective alternative treatments is escalating. Clinical studies have demonstrated promising outcomes with ultrasound-based renal denervation, showing significant reductions in blood pressure, which enhances physician confidence and drives market growth. Furthermore, these devices are associated with minimal vascular damage, which improves patient safety and widens their applicability to a broader range of patients, including those with complex comorbidities.

Additionally, technological advancements in ultrasound-based systems, such as automated feedback mechanisms and improved catheter designs, have also contributed to their growing market share. These innovations ensure better control during the procedure, leading to consistent results and fewer procedural errors. The integration of imaging technologies in some ultrasound-based devices further enhances precision by allowing real-time monitoring of the ablation process, a feature that is particularly attractive to clinicians.

In addition to efficacy and safety, the reduced recovery time associated with ultrasound-based renal denervation procedures is a key factor driving patient preference. Shorter hospital stays and quicker recovery periods make these devices a cost-effective solution for healthcare providers, thereby encouraging their adoption in both developed and emerging markets. Regulatory approvals for new ultrasound-based renal denervation devices, along with ongoing clinical trials to expand their indications, are further propelling market growth.

For instance, in November 2023, Otsuka Medical Devices Co., Ltd. and Recor Medical, Inc. announced the U.S. Food and Drug Administration (FDA) has approved Recor's Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of renal denervation devices across the globe.

North America is expected to dominate the overall renal denervation devices market:

North America is expected to account for the highest proportion of the renal denervation devices market in 2024, out of all regions. The region is anticipated to dominate the overall renal denervation devices market due to high healthcare spending, advanced infrastructure, and strong regulatory support. A large patient pool with hypertension and cardiovascular diseases drives demand for renal denervation devices while leading manufacturers like Medtronic and Boston Scientific contribute to innovation. FDA approvals and favorable reimbursement policies also boost market growth, making North America a key leader in the market.

According to recent data from the Centers for Disease Control and Prevention (2025), nearly half of adults have high blood pressure i.e. about 48.1%, 119.9 million in the United States.

Additionally, according to recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke. Hypertension is a major risk factor for both stroke and AF, which is increasing globally, leading to higher demand for treatments like renal denervation to manage blood pressure and prevent further complications. Renal denervation, by targeting sympathetic nerve activity in the kidneys, has shown promise in reducing hypertension and controlling arrhythmias like AF, which commonly coexists with high blood pressure. The growing incidence of these conditions, particularly stroke and AF, drives healthcare providers to seek more effective, non-pharmacological solutions. As the need for advanced treatments rises, renal denervation devices are positioned as key players in improving patient outcomes, thus expanding their market share and accelerating product development.

Furthermore, the increasing number of product development activities in the region is further going to accelerate the growth of the renal denervation devices market. For instance, in January 2025, Medtronic announced CMS national coverage analysis for Symplicity™ Spyral Renal Denervation System. This coverage decision implies that the device could become more widely reimbursed by Medicare and Medicaid, increasing its accessibility to a broader patient population. Medicare covers a large proportion of patients, particularly those with chronic hypertension, a key target for renal denervation therapies. By making this technology more financially accessible through reimbursement, more healthcare providers will likely adopt the Symplicity™ Spyral system, leading to higher demand and broader utilization in treating hypertension.

Thus, the above-mentioned factors are expected to escalate the market of renal denervation devices in the region.

Renal Denervation Devices Market Key Players:

Some of the key market players operating in the renal denervation devices market include Medtronic plc., ReCor Medical Inc., Boston Scientific Corporation, Ablative Solutions, Inc., Terumo Corporation, Autonomix Medical, Inc., Zeus Company LLC, Otsuka Medical Devices Co., Ltd., Koninklijke Philips N.V., Mercator MedSystems Inc., SoniVie, Plexus Corp., Kona Medical, Symple Surgical, Mercator MedSystems, and others.

Recent Developmental Activities in the Renal Denervation Devices Market:

• In September 2024, Autonomix Medical, Inc. completed a successful preclinical study showcasing the potential of its catheter-based sensing technology for renal denervation. The technology aims to make procedures safer and more effective by accurately locating nerves around the renal artery.
• In September 2023, Zeus launched next-generation tubing Absorv™ XSE, for bioRenal denervation devices.

Key Takeaways From the Renal Denervation Devices Market Report Study

• Market size analysis for current renal denervation devices size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the renal denervation devices market.
• Various opportunities available for the other competitors in the renal denervation devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current renal denervation devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for renal denervation devices market growth in the coming future?

Target Audience Who Can be Benefited From This Renal Denervation Devices Market Report Study

• Renal denervation devices product providers
• Research organizations and consulting companies
• Renal denervation devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in renal denervation devices
• Various end-users who want to know more about the renal denervation devices market and the latest technological developments in the renal denervation devices market. 

Frequently Asked Questions for the Renal Denervation Devices Market:

1. What are renal denervation devices?

• Renal denervation devices are medical tools designed to treat resistant hypertension and other cardiovascular conditions by disrupting nerve signals between the kidneys and the brain, using techniques like radiofrequency, ultrasound, or chemical ablation.

2. What is the market for renal denervation devices?

• The global renal denervation devices market is estimated to grow at a CAGR of 14.34% during the forecast period from 2025 to 2032.

3. What are the drivers for the global renal denervation devices market?

• The rising prevalence of hypertension and the growing incidence of cardiovascular diseases closely linked to uncontrolled blood pressure is significantly driving the demand for renal denervation devices. Additionally, the expansion of these devices into other clinical applications, such as heart failure and chronic kidney disease, has broadened their market potential. Continuous advancements in technology and increased product development activities by key players globally are further enhancing the safety, efficacy, and adoption of these devices, collectively fueling the growth of the renal denervation devices market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global renal denervation devices market?

• Some of the key market players operating in renal denervation devices are Medtronic plc., ReCor Medical Inc., Boston Scientific Corporation, Ablative Solutions, Inc., Terumo Corporation, Autonomix Medical, Inc., Zeus Company LLC, Otsuka Medical Devices Co., Ltd., Koninklijke Philips N.V., Mercator MedSystems Inc., SoniVie, Plexus Corp., Kona Medical, Symple Surgical, Mercator MedSystems, and others.

5. Which region has the highest share in the global renal denervation devices market?

• North America is expected to account for the highest proportion of the renal denervation devices market in 2024, out of all regions. The region is anticipated to dominate the overall renal denervation devices market due to high healthcare spending, advanced infrastructure, and strong regulatory support. A large patient pool with hypertension and cardiovascular diseases drives demand while leading manufacturers like Medtronic and Boston Scientific contribute to innovation. FDA approvals and favorable reimbursement policies also boost market growth, making North America a key leader in the market.